Objective To explore the role of pseudogene AC106872.1 in maintaining the self-renewal capacity of human embryonic stem cells(hESCs).Methods AC106872.1 was knocked out in hESCs and knockout effi-ciency was validated by PCR and agarose gel electrophoresis.The colony formation of hESCs was assessed through colony formation assays and alkaline phosphatase(AP)staining.The expression level of pluripotency and differ-entiation marker genes was analyzed by qPCR and flow cytometry.RNA sequencing(RNA-seq)was performed to assess transcriptomic changes upon AC106872.1 knockout.Results Knockout of AC106872.1 significantly in-hibited the colony formation of hESCs(P＜0.05).The expression level of pluripotency marker genes was signifi-cantly reduced(P＜0.000 1),while the expression of differentiation marker genes was markedly increased(P＜0.000 1).Conclusions The pseudogene AC 1 06872.1 plays a crucial role in maintaining human embryonic stem cell self-renewal through regulation of pluripotency genes expression.

Objective To investigate the effect of ergothioneine(EGT)on tissue metabolism in middle-aged and aged mice.Methods Nine-month-old middle-aged and aged C57BL/6J mice were selected to be gavaged with EGT aqueous solution at the dose and frequency of 35 mg EGT per kg body weight every two days.The control group was gavaged with the same amount of water.Both groups were fed with EGT-free diet.After 7 weeks,the liver,kidney,and small intestine of mice were collected,and untargeted metabolomics analysis was performed using ultra-per-formance liquid chromatography-mass spectrometry(UHPLC-MS).The differential metabolites were selected for KEGG metabolic pathway enrichment analysis.Results Compared with the control group,the abundances of me-tabolites related to redox balance in liver,kidney and small intestine of middle-aged and aged mice treated with EGT did not change significantly.However,taurine and hypotaurine metabolism in liver(P＜0.01),purine metabo-lism in kidney(P＜0.01),and cysteine and methionine metabolism in small intestine(P＜0.001)were affected.Conclusions Non-redox-related metabolic changes in the liver,kidney and small intestine of middle-aged and aged mice by ergothioheine.

Objective To investigate the effect of pseudogene GTF3AP2 in erythroid differentiation.Methods The published high-throughput RNA sequencing(RNA-seq)data were analyzed to identify the functional pseudogene GTF3AP2,which may play a role in erythropoiesis.The endogenous expression of GTF3AP2 was inhibited by shR-NA in CD34+hematopoietic stem/progenitor cells to assess the colony-forming ability through colony-forming assay.Flow cytometry analysis was applied to detect changes in the ratio of erythroid/megakaryocytic progenitor cells.Ad-ditionally,the role of GTF3AP2 in erythroid differentiation was determined through transcriptome sequencing,which revealed alterations at the cellular and molecular levels following the knockdown of GTF3AP2.Results Com-pared with the sh-EV group,knockdown of GTF3AP2 resulted in a significant increase in cell expansion,character-ized by a significant rise in the number of colony-forming unit erythroid cells(P＜0.001),an increase in the proportion of CD71+CD235a+erythroid precursors(P＜0.01),and a decrease in the proportion of CD71-CD235a+mature erythrocytes(P＜0.05).Furthermore,there was a significant reduction in the expression of key erythroid dif-ferentiation genes,including KLF1,HBB,GYPA,EPOR and TFRC.Conclusions Knocking down of GTF3AP2 promotes the expansion of erythroid precursor cells and inhibits erythroid maturation,suggesting that GTF3AP2 plays a regulatory role in erythroid differentiation.

ABSRACT The development of hepatocellular car-cinoma(HCC)is closely related to the formation of tumour blood vessels.VEGF-mediated angiogenesis is a major driver of the immune escape response in tumours.VEGF binds to vascular endothelial growth factor receptor2(VEGFR2)on endothelial cells,promoting endothelial cell proliferation and migration,inducing vascular changes in HCC,and thus promote the growth of hepatocellular carcino-ma cells.Anti-VEGF and its receptor-targeted mo-lecular drugs are currently effective new treat-ments for HCC.Monoclonal antibodies against VEGF and small-molecule tyrosine kinase inhibitors targeting VEGF have been shown to block its angio-genic activity,alleviate the inhibitory effect of the tumour microenvironment,and ultimately achieve tumour regression.This article provides a review of the research progress of VEGF/VEGFR inhibitors in HCC treatment.

ABSRACT The development of hepatocellular car-cinoma(HCC)is closely related to the formation of tumour blood vessels.VEGF-mediated angiogenesis is a major driver of the immune escape response in tumours.VEGF binds to vascular endothelial growth factor receptor2(VEGFR2)on endothelial cells,promoting endothelial cell proliferation and migration,inducing vascular changes in HCC,and thus promote the growth of hepatocellular carcino-ma cells.Anti-VEGF and its receptor-targeted mo-lecular drugs are currently effective new treat-ments for HCC.Monoclonal antibodies against VEGF and small-molecule tyrosine kinase inhibitors targeting VEGF have been shown to block its angio-genic activity,alleviate the inhibitory effect of the tumour microenvironment,and ultimately achieve tumour regression.This article provides a review of the research progress of VEGF/VEGFR inhibitors in HCC treatment.

ABSRACT The development of hepatocellular car-cinoma(HCC)is closely related to the formation of tumour blood vessels.VEGF-mediated angiogenesis is a major driver of the immune escape response in tumours.VEGF binds to vascular endothelial growth factor receptor2(VEGFR2)on endothelial cells,promoting endothelial cell proliferation and migration,inducing vascular changes in HCC,and thus promote the growth of hepatocellular carcino-ma cells.Anti-VEGF and its receptor-targeted mo-lecular drugs are currently effective new treat-ments for HCC.Monoclonal antibodies against VEGF and small-molecule tyrosine kinase inhibitors targeting VEGF have been shown to block its angio-genic activity,alleviate the inhibitory effect of the tumour microenvironment,and ultimately achieve tumour regression.This article provides a review of the research progress of VEGF/VEGFR inhibitors in HCC treatment.

ABSRACT The development of hepatocellular car-cinoma(HCC)is closely related to the formation of tumour blood vessels.VEGF-mediated angiogenesis is a major driver of the immune escape response in tumours.VEGF binds to vascular endothelial growth factor receptor2(VEGFR2)on endothelial cells,promoting endothelial cell proliferation and migration,inducing vascular changes in HCC,and thus promote the growth of hepatocellular carcino-ma cells.Anti-VEGF and its receptor-targeted mo-lecular drugs are currently effective new treat-ments for HCC.Monoclonal antibodies against VEGF and small-molecule tyrosine kinase inhibitors targeting VEGF have been shown to block its angio-genic activity,alleviate the inhibitory effect of the tumour microenvironment,and ultimately achieve tumour regression.This article provides a review of the research progress of VEGF/VEGFR inhibitors in HCC treatment.

ABSRACT The development of hepatocellular car-cinoma(HCC)is closely related to the formation of tumour blood vessels.VEGF-mediated angiogenesis is a major driver of the immune escape response in tumours.VEGF binds to vascular endothelial growth factor receptor2(VEGFR2)on endothelial cells,promoting endothelial cell proliferation and migration,inducing vascular changes in HCC,and thus promote the growth of hepatocellular carcino-ma cells.Anti-VEGF and its receptor-targeted mo-lecular drugs are currently effective new treat-ments for HCC.Monoclonal antibodies against VEGF and small-molecule tyrosine kinase inhibitors targeting VEGF have been shown to block its angio-genic activity,alleviate the inhibitory effect of the tumour microenvironment,and ultimately achieve tumour regression.This article provides a review of the research progress of VEGF/VEGFR inhibitors in HCC treatment.

ABSRACT The development of hepatocellular car-cinoma(HCC)is closely related to the formation of tumour blood vessels.VEGF-mediated angiogenesis is a major driver of the immune escape response in tumours.VEGF binds to vascular endothelial growth factor receptor2(VEGFR2)on endothelial cells,promoting endothelial cell proliferation and migration,inducing vascular changes in HCC,and thus promote the growth of hepatocellular carcino-ma cells.Anti-VEGF and its receptor-targeted mo-lecular drugs are currently effective new treat-ments for HCC.Monoclonal antibodies against VEGF and small-molecule tyrosine kinase inhibitors targeting VEGF have been shown to block its angio-genic activity,alleviate the inhibitory effect of the tumour microenvironment,and ultimately achieve tumour regression.This article provides a review of the research progress of VEGF/VEGFR inhibitors in HCC treatment.

ABSRACT The development of hepatocellular car-cinoma(HCC)is closely related to the formation of tumour blood vessels.VEGF-mediated angiogenesis is a major driver of the immune escape response in tumours.VEGF binds to vascular endothelial growth factor receptor2(VEGFR2)on endothelial cells,promoting endothelial cell proliferation and migration,inducing vascular changes in HCC,and thus promote the growth of hepatocellular carcino-ma cells.Anti-VEGF and its receptor-targeted mo-lecular drugs are currently effective new treat-ments for HCC.Monoclonal antibodies against VEGF and small-molecule tyrosine kinase inhibitors targeting VEGF have been shown to block its angio-genic activity,alleviate the inhibitory effect of the tumour microenvironment,and ultimately achieve tumour regression.This article provides a review of the research progress of VEGF/VEGFR inhibitors in HCC treatment.